Evidence map›Paper›PMID 32616077›Full record

SynthesisCritical care (London, England)2020

Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis.

Nicola Potere, Emanuele Valeriani, Matteo Candeloro, Marco Tana, Ettore Porreca, Antonio Abbate, Silvia Spoto, Anne W S Rutjes, Marcello Di Nisio

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Colchicine for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  8. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  9. Pooled it
  10. Systematic Review on Outbreaks of SARS-CoV-2 on Cruise, Navy and Cargo Ships.International journal of environmental research and public health · 2021
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicola PotereDepartment of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Via Dei Vestini 31, 66100, Chieti, Italy.
Emanuele ValerianiDepartment of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Via Dei Vestini 31, 66100, Chieti, Italy. emanuele.valeriani@outlook.com.ORCID http://orcid.org/0000-0001-9729-3214
Matteo CandeloroDepartment of Medicine and Ageing Sciences, "G. d'Annunzio" University, Chieti-Pescara, Italy.
Marco TanaDepartment of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Via Dei Vestini 31, 66100, Chieti, Italy.
Ettore PorrecaDepartment of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Via Dei Vestini 31, 66100, Chieti, Italy.
Antonio AbbateVCU Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Silvia SpotoInternal Medicine Department, University Hospital Campus Bio-Medico, Rome, Italy.
Anne W S RutjesInstitute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Marcello Di NisioDepartment of Medicine and Ageing Sciences, "G. d'Annunzio" University, Chieti-Pescara, Italy.

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
NCATS NIH HHS UL1 TR002649
6 · The paper itself

Abstract

backgroundThe incidence of acute complications and mortality associated with COVID-19 remains poorly characterized. The aims of this systematic review and meta-analysis were to summarize the evidence on clinically relevant outcomes in hospitalized patients with COVID-19.

methodsMEDLINE, EMBASE, PubMed, and medRxiv were searched up to April 20, 2020, for studies including hospitalized symptomatic adult patients with laboratory-confirmed COVID-19. The primary outcomes were all-cause mortality and acute respiratory distress syndrome (ARDS). The secondary outcomes included acute cardiac or kidney injury, shock, coagulopathy, and venous thromboembolism. The main analysis was based on data from peer-reviewed studies. Summary estimates and the corresponding 95% prediction intervals (PIs) were obtained through meta-analyses.

resultsA total of 44 peer-reviewed studies with 14,866 COVID-19 patients were included. In general, risk of bias was high. All-cause mortality was 10% overall (95% PI, 2 to 39%; 1687/14203 patients; 43 studies), 34% in patients admitted to intensive care units (95% PI, 8 to 76%; 659/2368 patients; 10 studies), 83% in patients requiring invasive ventilation (95% PI, 1 to 100%; 180/220 patients; 6 studies), and 75% in patients who developed ARDS (95% PI, 35 to 94%; 339/455 patients; 11 studies). On average, ARDS occurred in 14% of patients (95% PI, 2 to 59%; 999/6322 patients; 23 studies), acute cardiac injury in 15% (95% PI, 5 to 38%; 452/2389 patients; 10 studies), venous thromboembolism in 15% (95% PI, 0 to 100%; patients; 3 studies), acute kidney injury in 6% (95% PI, 1 to 41%; 318/4682 patients; 15 studies), coagulopathy in 6% (95% PI, 1 to 39%; 223/3370 patients; 9 studies), and shock in 3% (95% PI, 0 to 61%; 203/4309 patients; 13 studies).

conclusionsMortality was very high in critically ill patients based on very low-quality evidence due to striking heterogeneity and risk of bias. The incidence of clinically relevant outcomes was substantial, although reported by only one third of the studies suggesting considerable underreporting.

trial registrationPROSPERO registration ID for this study is CRD42020177243 ( https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=177243 ).

Indexed as

Coronavirus InfectionsCOVID-19HospitalizationHumansObservational Studies as TopicPandemicsPneumonia, ViralRandomized Controlled Trials as TopicTreatment OutcomeAdult respiratory distress syndromeCoronavirusCOVID-19Oxygen inhalation therapySARS virus

Identifiers

PMID32616077
PMCPMC7330272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.